The effects of acute kidney injury extend beyond the acute illness phase.

Knowledge of common injuries and a clear understanding of an athlete’s goals are the bases for successful injury management.

This article presents a clinically useful guide for GPs to support the primary management of chemical-related eye injuries, particularly in rural and regional settings.

This issue focuses on rheumatology and includes articles on acute rheumatic fever, rheumatoid arthritis and the role of exercise in management of rheumatological disease.

Successful implementation of evidence-based medicine requires framing within the cultural and structural barriers Aboriginal and Torres Strait Islander people experience.

Timely use of appropriate imaging for sports injuries is required for optimal outcomes.

The aim of this review is to draw attention to a preventable childhood condition, detailing the clinical presentation, diagnostic pathway and management.

The Focus articles in this issue explore COVID-19 renal disease, acute kidney injury, renal colic, paediatric urinary tract infections and haematuria.

The interface of general practice and kidney healthcare has never been more important than it is in our current pandemic world.

Patients can be empowered through understanding chronic kidney disease as not confined to a single organ system but as the antecedent and consequence of several pathophysiological processes.

The Focus articles in this issue explore various aspects of chronic kidney disease, as well as cystitis symptoms in women.

Intentional aerosol skin injuries present a double blow to effective clinical management – a severe burn that is both poorly reported and underestimated by the patient.

Acute-onset walking difficulties in a six-year-old boy recovering from a viral upper respiratory tract infection.

A stepwise approach to a patient with renal tract pain can aid immensely in formulating an accurate diagnosis and providing optimal care.

This article aims to provide evidence-based information to GPs, aiding the decision to initiate sodium–glucose cotransporter 2 (SGLT2) inhibitors for chronic kidney disease patients.